These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

897 related items for PubMed ID: 33373830

  • 1. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H, Berrou J, Dupont M, Kaci A, Ehlert JE, Weber H, Baruchel A, Paublant F, Prudent R, Gardin C, Dombret H, Braun T.
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.
    Clin Cancer Res; 2019 Nov 15; 25(22):6815-6826. PubMed ID: 31320594
    [Abstract] [Full Text] [Related]

  • 3. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
    Long J, Jia MY, Fang WY, Chen XJ, Mu LL, Wang ZY, Shen Y, Xiang RF, Wang LN, Wang L, Jiang CH, Jiang JL, Zhang WJ, Sun YD, Chang L, Gao WH, Wang Y, Li JM, Hong DL, Liang AB, Hu J.
    Blood; 2020 Apr 23; 135(17):1472-1483. PubMed ID: 32315388
    [Abstract] [Full Text] [Related]

  • 4. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, Janke LJ, Ramachandran A, Stewart CF, Inaba H, Baker SD.
    Blood; 2013 Nov 21; 122(22):3607-15. PubMed ID: 24046014
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G.
    J Hematol Oncol; 2013 Mar 16; 6():21. PubMed ID: 23497456
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
    Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y.
    Oncotarget; 2015 Oct 20; 6(32):33410-25. PubMed ID: 26450903
    [Abstract] [Full Text] [Related]

  • 15. Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD).
    Lu JW, Wang AN, Liao HA, Chen CY, Hou HA, Hu CY, Tien HF, Ou DL, Lin LI.
    Cancer Lett; 2016 Jul 01; 376(2):218-25. PubMed ID: 27060207
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways.
    Yu M, Fang ZX, Wang WW, Zhang Y, Bu ZL, Liu M, Xiao XH, Zhang ZL, Zhang XM, Cao Y, Wang YY, Lei H, Xu HZ, Wu YZ, Liu W, Wu YL.
    Acta Pharmacol Sin; 2021 Apr 01; 42(4):604-612. PubMed ID: 32694757
    [Abstract] [Full Text] [Related]

  • 18. Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling.
    Chen M, Shen C, Chen Y, Chen Z, Zhou K, Chen Y, Li W, Zeng C, Qing Y, Wu D, Xu C, Tang T, Che Y, Qin X, Xu Z, Wang K, Leung K, Sau L, Deng X, Hu J, Wu Y, Chen J.
    Cell Rep Med; 2024 Jul 16; 5(7):101645. PubMed ID: 39019012
    [Abstract] [Full Text] [Related]

  • 19. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F, Huang J, Guo T, Zheng Y, Zhang L, Zhang D, Wang F, Naren D, Cui Y, Liu X, Qu Y, Luo H, Yang Y, Wei H, Guo Y.
    Biochem Pharmacol; 2021 Jun 16; 188():114538. PubMed ID: 33831397
    [Abstract] [Full Text] [Related]

  • 20. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S.
    Leukemia; 2012 Jul 16; 26(7):1462-70. PubMed ID: 22354205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.